Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01746251 | Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation | unknown | Phase 2 | 92 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03987867 | Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04193098 | Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC | unknown | Phase 1 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04455984 | Multimodality Treatment Including Curative Resection of Advanced NSCLC | unknown | — | 190 | Medical University of ViennaOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04459663 | JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. | unknown | Phase 2 | 50 | Li Zhang, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04455594 | Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC(ANSWER) | unknown | Phase 2 | 168 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453423 | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2020 | clinicaltrials |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT03634826 | Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).(MEDAL) | unknown | — | 200 | Peking University People's HospitalOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT04440800 | Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment(WATTOX) | unknown | — | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT03571360 | CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients | unknown | Phase 2 | 42 | Medical University of ViennaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03983759 | Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04397926 | Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04425681 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer(OWBLM) | unknown | Phase 2 | 20 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04419935 | Lymphadenectomy in NSCLC With and Without Adjuvant Therapy | unknown | — | 250 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04413227 | A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04115410 | PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study | unknown | — | 4,724 | Sungkyunkwan UniversityOTHER | 0 | May 28, 2020 | clinicaltrials |
| NCT04404543 | A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer | unknown | Phase 1 | 71 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | May 27, 2020 | clinicaltrials |
| NCT04153799 | Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 | 11 | Sun Yat-sen UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT04203485 | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 762 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 8, 2020 | clinicaltrials |
| NCT04371796 | Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | May 1, 2020 | clinicaltrials |
| NCT04363255 | First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC | unknown | Phase 2 | 20 | Taizhou HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT04358562 | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | unknown | Phase 2 | 240 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04355806 | Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors | unknown | — | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT03130192 | A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy | unknown | — | 60 | Chung Shan Medical UniversityOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT04339829 | An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | unknown | Phase 2 | 50 | Guangdong Association of Clinical TrialsOTHER | 0 | Apr 9, 2020 | clinicaltrials |
| NCT03706287 | Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC | unknown | Phase 1 / Phase 2 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT03940846 | CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology | unknown | — | 650 | Maastricht UniversityOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT04333004 | Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | unknown | Phase 1 / Phase 2 | 40 | Xiaorong DongOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT04331626 | Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC | unknown | Phase 4 | 50 | Henan Cancer HospitalOTHER_GOV | 0 | Apr 2, 2020 | clinicaltrials |
| NCT04326751 | Evolution of Multiple Primary Lung Cancer (Evolution) | unknown | — | 20 | Peking University People's HospitalOTHER | 0 | Mar 30, 2020 | clinicaltrials |
| NCT03371992 | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC(NO3DEXPL) | unknown | Early Phase 1 | 25 | Nilogen OncosystemsINDUSTRY | 1 | Mar 27, 2020 | clinicaltrials |
| NCT03823625 | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)(SQUINT) | unknown | Phase 2 | 112 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04317651 | Crizotinib in ALK Rearranged Non-small-cell Lung Cancer(SPECIALK) | unknown | — | 500 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03764917 | NGS Combined With RNAseq on Tumor Immune Escape in NSCLC | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT04314297 | Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | unknown | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 19, 2020 | clinicaltrials |
| NCT03119519 | Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer. | unknown | Phase 2 | 148 | Southern Medical University, ChinaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02076477 | The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）(OITROLC) | unknown | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT04306042 | A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy | unknown | — | 1,000 | Guangdong Association of Clinical TrialsOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT04306094 | Factors Determining the Prognosis in NSCLC Stage IV(LUPROG) | unknown | — | 217 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT04304638 | Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC | unknown | — | 450 | Chinese Academy of Medical SciencesOTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT04303130 | Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC | unknown | Phase 2 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03130881 | Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. | unknown | Phase 1 | 60 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03585998 | Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer | unknown | Phase 2 | 51 | Samsung Medical CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04284202 | PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC | unknown | Phase 2 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01405079 | Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation(ADJUVANT) | unknown | Phase 3 | 222 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT04266483 | Cancer Genome Atlas of China:Lung Cancer | unknown | — | 2,500 | Xuanwu Hospital, BeijingOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02725918 | Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure | unknown | Phase 2 | 150 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 12, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 7, 2020source: clinicaltrials